XVIVO Perfusion AB
30.9.2021 09:02:09 CEST | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / September 30, 2021 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)
The following members have been appointed to XVIVO Perfusion's nomination committee for the 2022 annual general meeting:
Henrik Blomquist, appointed by Bure Equity AB
Caroline Sjösten appointed by Swedbank Robur Fonder AB
Thomas Ehlin, appointed by The Fourth Swedish National Pension Fund
Gösta Johannesson, chairman of the board of directors
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company's nomination committee which were established by the annual general meeting of XVIVO Perfusion AB (publ) on April 27, 2018. The shareholders that have appointed the members of the nomination committee represented in aggregate 32 percent of all shares in the company as of 31 August 2021.
The nomination committee shall prepare and submit proposals to the annual general meeting 2022 regarding (i) election of chairman of the meeting, (ii) resolution on number of board members, (iii) election of and resolution on remuneration to the chairman of the board and the board members, (iv) election of and resolution on remuneration to the auditor, and (v) resolution on new procedure for appointing the nomination committee if the nomination committee deems it to be necessary.
The annual general meeting of XVIVO Perfusion AB (publ) will be held on April 26, 2022 in Gothenburg. Shareholders who wish to submit proposals to the nomination committee are welcome to do so in due time before the annual general meeting so that the nomination committee has time to consider the proposal. Proposals may be sent to XVIVO Perfusion AB (publ), Att: Nomination committee, P.O. Box 53015, SE‑400 14 Gothenburg, Sweden.
September 30, 2021
XVIVO Perfusion AB (publ)
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
SOURCE: XVIVO Perfusion AB
View source version on accesswire.com:
https://www.accesswire.com/666221/Nomination-Committee-of-XVIVO-Perfusion-AB-publ
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Nexteer Announces First Share Repurchase Programme of Up to US$60 Million12.11.2026 01:40:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / November 11, 2026 / Nexteer Automotive today announced that its Board of Directors has approved, the Company's first share repurchase programme of up to US$60 million, equivalent to approximately HK$471 million. The programme reflects the Board's confidence in Nexteer's business and long-term prospects. The Group's strong liquidity position supports returning capital to shareholders while continuing to invest in the business and its future development. Disciplined Capital Allocation The programme complements Nexteer's dividend distributions and represents a further step in returning capital to shareholders. It follows the dividend paid out in July 2026 of approximately US$46 million, representing 45% of the Company's net income attributable to shareholders for the year ending December 31, 2025 -and the highest dividend payout ratio in the Company's history. Nexteer remains committed to disciplined capital allocation, balancing investment in the busines
GoodData.AI Launches the Agentic Serving Plane, a New Category of Enterprise Data Infrastructure for AI Agents10.11.2026 15:30:00 CET | Press release
SAN FRANCISCO, CA / ACCESS Newswire / November 10, 2026 / GoodData.AI, the open agentic analytics platform, today launched the Agentic Serving Plane, a governed execution layer designed for the high-concurrency, context-rich data workloads created by AI agents. The Agentic Serving Plane sits between enterprise data platforms and the applications, analytics experiences and agents that consume them. It provides workload serving, business semantics, contextual grounding, access control, and AI execution services through a common governed layer. The current enterprise data infrastructure was designed primarily for humans: occasional queries, predictable workloads, and access by known users. AI agents operate differently. A single business task can generate tens or hundreds of short-lived data operations as an agent investigates, reasons, and decides what to ask next. When many agents operate simultaneously, intermittent human querying becomes continuous, high-concurrency agentic demand. Ag
Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian10.11.2026 15:00:00 CET | Press release
FAIRFIELD, CT / ACCESS Newswire / November 10, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, has appointed Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian. Siino will lead a team providing best-in-class launch and revenue management services to the biopharma community. Pharma and biotech companies across the industry seek suppliers who can support them from their earliest stages, often before they have built in-house commercial, market access, and revenue management capabilities. Two Labs provides commercialization services and consulting support as these companies prepare for and execute successful launches; Riparian offers consulting, managed services, and technology to manage and protect revenue as their therapies reach patients. Together, Envision's Two Labs and Riparian businesses offer a single, connected solution spanning launch and beyond. Under Siino's leadership, clients wi
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations10.11.2026 14:00:00 CET | Press release
LINCOLN, NE / ACCESS Newswire / November 10, 2026 / Securitas Healthcare, a leading provider of real-time visibility and protection solutions for the healthcare industry, today announced the next generation of its MobileView® Real-Time Location System (RTLS) platform. The expanded platform introduces MobileView Cloud, new solution capabilities, enhanced user experiences, and flexible deployment, technology, and integration options that help healthcare organizations transform real-time visibility into operational intelligence. As health systems navigate workforce shortages, capacity constraints, and growing demands for efficiency and better patient experiences, timely access to operational and clinical information has become essential to managing increasingly complex care environments. Today's RTLS platforms provide the visibility and intelligence needed to improve patient throughput, enhance safety, optimize resource utilization, and support the connected operations required to enable
Opti Digital Launches NEXA, an AI-Powered Intelligence Layer9.11.2026 12:00:00 CET | Press release
PARIS, FR / ACCESS Newswire / November 9, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the launch of NEXA, its AI-powered intelligence layer designed to connect signals across the Opti Digital platform and help publisher teams make faster, better-informed decisions. Publisher teams work with revenue data, bidder signals, inventory changes, traffic shifts, alerts and dashboards as part of their daily operations. The opportunity lies in connecting these signals quickly enough to understand what changed, what is driving performance, what deserves attention and where teams should focus next. By streamlining how teams investigate performance changes, NEXA is designed to help them move faster from a signal to an informed decision. NEXA's first client-facing capability, NEXA AI Assistant, brings conversational analysis into publisher monetisation workflows. Connecting the Dots in Monetisation Through NEXA AI Assistant, users c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom